DelveInsight's " Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some key facts of DLBCL Market:

  • The total incident cases of DLBCL in the 7MM was assessed to be 67,743 in 2017, and are expected to increase during the study period (2017-2030).
  • It was observed that the age-group with the highest incidence among the 7MM was 65 74 years in 2017. Patients of age group 5564 years were observed to be the second-highest in 2017.
  • Among the EU5 countries, Germany had the highest incident population of DLBCL with 7,443 cases, followed by the United Kingdom and France, while Spain had the lowest incident cases in 2017.
  • Japan had 9,485 cases for DLBCL in 2017, which accounted for nearly 14% of the total 7MM patient population of DLBCL.

View Report:

Request for Free Sample Report:

Scope of the DLBCL Market Report:

  • Diffuse Large B-cell Lymphoma market report provides an in-depth analysis of Diffuse Large B-cell Lymphoma Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
  • The Diffuse Large B-cell Lymphoma market report will help in developing business strategies by understanding the Diffuse Large B-cell Lymphoma Market trends & developments, key players and future market competition that will shape and drive the Diffuse Large B-cell Lymphoma market in the upcoming years.
  • The Diffuse Large B-cell Lymphoma market report covers Diffuse Large B-cell Lymphoma current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
  • The report provides a detailed assessment of the Diffuse Large B-cell Lymphoma market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.

DLBCL Companies Covered:

  • MorphoSys
  • ADC Therapeutics
  • Cellectar
  • Karyopharm Therapeutics
  • And Many others

View Report:

Request for Free Sample Report:

Diffuse Large B-cell Lymphoma (DLBCL) is “a diffuse proliferation of large neoplastic B lymphoid cells with a nuclear size equal to or exceeding normal macrophage nuclei or more than twice the size of a normal lymphocyte.”

DLBCL is a heterogeneous entity that includes a number of different variants and subtypes, with the current interest in identifying additional prognostically meaningful subsets. It occurs in young adults around age 35 and it affects slightly more women than men.

Diffuse large B-cell lymphoma grows rapidly in the lymph nodes and frequently involves the spleen, liver, bone marrow or other organs. Usually, DLBCL development starts in lymph nodes in the neck or abdomen and is characterized by masses of large B cells.

The most common symptom is painless swelling in the neck, armpit or groin. Other symptoms may include:.

  • Tiredness
  • Weight loss
  • Night sweats
  • High temperatures (fevers).

In 2016’s WHO updated classification, DLBCL is divided in to following entities, DLBCL, NOS (not otherwise specified); DLBCL subtypes (such as, T-cell/histiocyte-rich Large B-cell Lymphoma; Primary DLBCL of the central nervous system; Primary cutaneous DLBCL, leg type; EBV positive DLBCL, NOS) and Other lymphomas of large B-cells.

According to the Lymphoma Research Foundation, the occurrence of DLBCL generally increases with age, and most patients are over the age of 60 at diagnosis. It is more prevalent in male as compared to female.

View Report:

Request for Free Sample Report:

DLBCL Drugs Covered:

  • MOR208
  • ADCT-402
  • CLR 131
  • Selinexor
  • And Many Others

Table of Contents:

  1. Key Insights
  2. Executive Summary of Diffuse Large B-cell Lymphoma
  3. Competitive Intelligence Analysis for Diffuse Large B-cell Lymphoma
  4. Diffuse Large B-cell Lymphoma: Market Overview at a Glance
  5. Diffuse Large B-cell Lymphoma: Disease Background and Overview

5.1. Introduction

  1. Treatment Algorithm, Current Treatment, and Medical Practices
  2. Unmet Needs
  3. Key Endpoints of Diffuse Large B-cell Lymphoma Treatment
  4. Marketed Products

List to be continued in report

  1. Emerging Therapies

List to be continued in report

  1. Diffuse Large B-cell Lymphoma: Seven Major Market Analysis
  2. Attribute analysis
  3. 7MM: Market Outlook
  4. Access and Reimbursement Overview of Diffuse Large B-cell Lymphoma
  5. KOL Views
  6. Market Drivers
  7. Market Barriers
  8. Appendix

20.1. Bibliography

20.2. Report Methodology

  1. DelveInsight Capabilities
  2. Disclaimer
  3. About DelveInsight

View Report:

Request for Detailed TOC:

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for

Browse through our vast repository from here.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: [email protected]
Phone: +19193216187
City: Albany
State: New York
Country: United States